MedTrace Logo

Ruxolitinib as GVHD Prophylaxis in AA Patients

NCT05914714 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 46

Last updated 2023-06-22

No results posted yet for this study

Summary

Our study aimed to determine the prophylactic value of ruxolitinib for aGVHD in HSCT recipients of AA.Ruxolitinib was initiated at the beginning of conditioning regimen at 5 twice daily until 3 months post-transplantation. The cumulative incidence of aGVHD within 6 months after HSCT will be the primary observation item.

Conditions

  • The Prophylactic Value of Ruxolitinib for aGVHD in HSCT Recipients of AA

Interventions

DRUG

Ruxolitinib 5 MG BID Oral Tablet

ruxolitinib 5mgBID will be administrated at the beginning of the conditioning regimen until 3 months post-transplantation.

Sponsors & Collaborators

  • Institute of Hematology & Blood Diseases Hospital, China

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
14 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-07-01
Primary Completion
2025-05-01
Completion
2025-05-01
FDA Drug
Yes

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05914714 on ClinicalTrials.gov